SCHEMBL1355784

SCHEMBL1355784

COc1ccc(-n2ncc3cnc(Nc4ccc5c(c4)OCCO5)nc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 2/20 0.59
SYK P43405 3/20 0.54
TBK1 Q9UHD2 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
GSK3B P49841 2/20 0.50
MAPT P10636 7/20 0.48
BRD4 O60885 2/20 0.47
CDK4 P11802 1/20 0.46
CDK2 P24941 1/20 0.46
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
STK33 Q9BYT3 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355806 0.97 EIF2AK4 (0.56) EIF2AK4SYKTBK1MEN1KMT2A
SCHEMBL1353591 0.97 EIF2AK4 (0.56) EIF2AK4SYKTBK1MEN1KMT2A
SCHEMBL1356669 0.96 EIF2AK4 (0.57) EIF2AK4SYKTBK1MEN1KMT2A
SCHEMBL1356713 0.88 MAPT (0.51) EIF2AK4SYKGSK3BMAPTBRD4
SCHEMBL1355208 0.85 EIF2AK4 (0.58) EIF2AK4TBK1MEN1KMT2AMAPT
SCHEMBL1355678 0.84 TUBB4A (0.48) EIF2AK4SYKMEN1KMT2AMAPT
SCHEMBL1355771 0.82 EIF2AK4 (0.64) EIF2AK4TBK1MEN1KMT2AMAPT
SCHEMBL1355170 0.82 EIF2AK4 (0.61) EIF2AK4SYKTBK1MEN1KMT2A
SCHEMBL1353635 0.81 EIF2AK4 (0.66) EIF2AK4SYKTBK1MEN1KMT2A
SCHEMBL1356186 0.80 EIF2AK4 (0.67) EIF2AK4SYKTBK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885SYK 1152/4885TBK1 1295/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885SYK 1152/4885TBK1 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.